Lobbying in Healthcare

Lobbying in the United States

Main article: Lobbying in the USA

2021: US pharmaceutical companies lobbying spending reached $123 million

At the end of January 2022, the non-profit organization Open Secrets posted the results on the expenses for 2021 of American pharmaceutical and biopharmaceutical companies for lobbying their interests in the United States. The total amount for lobbying is $123 million.

Open Secrets tracks campaign finance and lobbying data. Open Secrets data are based on documents from the US Senate Office of State Archives for 2021. Pfizer topped the list of the largest pharmaceutical companies, spending nearly $7.3 million on lobbying. AstraZeneca and pharmaceutical Novartis spent about $1.5 million on lobbying in the last quarter, which is almost double that of the same period in 2020. Novartis listed the proposed NIH agency, to be known as the Advanced Health Research Projects Agency as a central point, as well as biosimilars, priorities of PDUFA VII and Cures 2.0.

AbbVie spent almost $1.3 million in Q4, ending 2021 with expenses of about $1 million more compared to 2020. The company listed several separate bills as lobbying issues, including the law - On maintaining access to low-cost generics and biosimilars. The law will limit transactions that prevent or delay the release of generics, as well as another bill aimed at combating the transition to updated drugs. Some pharmaceutical companies, including Amgen and Bayer, lobbied against a law allowing US citizens and authorities to import cheaper drugs from other countries.

GSK also spent more than $1 million on lobbying in 2021 compared to 2020. Along with individual companies, industrial groups PhRMA and BIO conducted more active lobbying activities. House Speaker Nancy Pelosi's bill topped a list of lobbying issues cited by companies, as the bill would introduce price negotiations that could cost industry more than $100 billion through 2040.

Pharmaceutical production, lobbying in the United States for 2021:

• Pharmaceutical Research & Manufacturers of America - $22 млн;
• Horizon Therapeutics - $7,5 млн;
• Pfizer - $7.2 million;
• Merck - $6.5 million;
• AbbVie - $5.7 million;
• Novartis AG - $5.1 million;
• Eli Lilly - $4.8 million;
• Bristol-Myers Squibb - $4,7 млн;
• Bayer AG - $4.6 million;
• GlaxoSmithKline - $4.3 million;
• Takeda Pharmaceutical - $4 млн.^[1]

Notes